Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2017

Open Access 01-12-2017 | Review

Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines

Authors: Marcia Cruz-Correa, Julyann Pérez-Mayoral, Julie Dutil, Miguel Echenique, Rafael Mosquera, Keila Rivera-Román, Sharee Umpierre, Segundo Rodriguez-Quilichini, Maria Gonzalez-Pons, Myrta I. Olivera, Sherly Pardo, on behalf of the Puerto Rico Clinical Cancer Genetics Consortia

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2017

Login to get access

Abstract

Hereditary cancer predisposition syndromes comprise approximately 10% of diagnosed cancers; however, familial forms are believed to account for up to 30% of some cancers. In Hispanics, the most commonly diagnosed hereditary cancers include colorectal cancer syndromes such as, Lynch Syndrome, Familial Adenomatous Polyposis, and hereditary breast and ovarian cancer syndromes. Although the incidence of hereditary cancers is low, patients diagnosed with hereditary cancer syndromes are at high-risk for developing secondary cancers. Furthermore, the productivity loss that occurs after cancer diagnosis in these high-risk patients has a negative socio-economic impact. This review summarizes the genetic basis, phenotype characteristics, and the National Comprehensive Cancer Network’s screening, testing, and surveillance guidelines for the leading hereditary cancer syndromes. The aim of this review is to promote a better understanding of cancer genetics and genetic testing in Hispanic patients.
Literature
3.
go back to reference Siegel RL, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65(6):457–80.CrossRefPubMed Siegel RL, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65(6):457–80.CrossRefPubMed
4.
go back to reference Howlader N, et al. SEER cancer statistics review. J Natl Cancer Inst. 2013. Howlader N, et al. SEER cancer statistics review. J Natl Cancer Inst. 2013.
5.
go back to reference Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2013/​, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
6.
go back to reference Beggs AD, Hodgson SV. Genomics and breast cancer: the different levels of inherited susceptibility. Eur J Hum Genet. 2009;17(7):855–6.CrossRefPubMed Beggs AD, Hodgson SV. Genomics and breast cancer: the different levels of inherited susceptibility. Eur J Hum Genet. 2009;17(7):855–6.CrossRefPubMed
7.
go back to reference Pal T, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807–16.CrossRefPubMed Pal T, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807–16.CrossRefPubMed
9.
go back to reference Weitzel JN, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol. 2013;31(2):210–6.CrossRefPubMed Weitzel JN, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol. 2013;31(2):210–6.CrossRefPubMed
10.
go back to reference Weitzel JN, et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1615–20.CrossRefPubMed Weitzel JN, et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1615–20.CrossRefPubMed
11.
go back to reference John EM, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007;298(24):2869–76.CrossRefPubMed John EM, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007;298(24):2869–76.CrossRefPubMed
12.
go back to reference Ashton-Prolla P, Vargas FR. Prevalence and impact of founder mutations in hereditary breast cancer in Latin America. Genet Mol Biol. 2014;37(1 Suppl):234–40.CrossRefPubMed Ashton-Prolla P, Vargas FR. Prevalence and impact of founder mutations in hereditary breast cancer in Latin America. Genet Mol Biol. 2014;37(1 Suppl):234–40.CrossRefPubMed
13.
go back to reference Gomes MC, et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat. 2007;103(3):349–53.CrossRefPubMed Gomes MC, et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat. 2007;103(3):349–53.CrossRefPubMed
14.
go back to reference Lourenco JJ, et al. BRCA1 mutations in Brazilian patients. Genet Mol Biol. 2004;27:500–4.CrossRef Lourenco JJ, et al. BRCA1 mutations in Brazilian patients. Genet Mol Biol. 2004;27:500–4.CrossRef
15.
go back to reference Gutierrez-Espeleta G, et al. BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. Clin Genet. 2012;82:484–8.CrossRefPubMed Gutierrez-Espeleta G, et al. BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. Clin Genet. 2012;82:484–8.CrossRefPubMed
16.
go back to reference Gonzalez-Hormazabal P, et al. Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Breast Cancer Res Treat. 2011;126(3):705–16.CrossRefPubMed Gonzalez-Hormazabal P, et al. Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Breast Cancer Res Treat. 2011;126(3):705–16.CrossRefPubMed
17.
go back to reference Gallardo M, et al. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat. 2006;95(1):81–7.CrossRefPubMed Gallardo M, et al. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat. 2006;95(1):81–7.CrossRefPubMed
18.
go back to reference Solano AR, et al. BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus. 2012;1:20.CrossRefPubMedPubMedCentral Solano AR, et al. BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus. 2012;1:20.CrossRefPubMedPubMedCentral
19.
go back to reference Abugattas J, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet. 2015;88(4):371–5.CrossRefPubMed Abugattas J, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet. 2015;88(4):371–5.CrossRefPubMed
20.
go back to reference Rodriguez AO, et al. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol. 2012;124(2):236–43.CrossRefPubMed Rodriguez AO, et al. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol. 2012;124(2):236–43.CrossRefPubMed
21.
go back to reference Torres D, et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat. 2007;103(2):225–32.CrossRefPubMed Torres D, et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat. 2007;103(2):225–32.CrossRefPubMed
22.
go back to reference Lara K, et al. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res. 2012;45(2):117–30.CrossRefPubMed Lara K, et al. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res. 2012;45(2):117–30.CrossRefPubMed
23.
go back to reference Donenberg T, et al. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat. 2011;125(2):591–6.CrossRefPubMed Donenberg T, et al. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat. 2011;125(2):591–6.CrossRefPubMed
24.
go back to reference Rodriguez RC, et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer. 2008;7(3):275–9.CrossRefPubMed Rodriguez RC, et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer. 2008;7(3):275–9.CrossRefPubMed
25.
26.
go back to reference Dutil J, et al. The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat. 2015;154(3):441–53.CrossRefPubMedPubMedCentral Dutil J, et al. The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. Breast Cancer Res Treat. 2015;154(3):441–53.CrossRefPubMedPubMedCentral
27.
go back to reference Calderon-Garcidueñas AL, et al. Clinical follow-up of Mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Salud Publica de Mexico. 2005;47:110–5.CrossRefPubMed Calderon-Garcidueñas AL, et al. Clinical follow-up of Mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Salud Publica de Mexico. 2005;47:110–5.CrossRefPubMed
28.
go back to reference Blay P, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 2013;13:243.CrossRefPubMedPubMedCentral Blay P, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 2013;13:243.CrossRefPubMedPubMedCentral
29.
go back to reference Fachal L, et al. Large genomic rearrangements of BRCA1 and BRCA2 among patients referred for genetic analysis in Galicia (NW Spain): delimitation and mechanism of three novel BRCA1 rearrangements. PLoS One. 2014;9(3):e93306.CrossRefPubMedPubMedCentral Fachal L, et al. Large genomic rearrangements of BRCA1 and BRCA2 among patients referred for genetic analysis in Galicia (NW Spain): delimitation and mechanism of three novel BRCA1 rearrangements. PLoS One. 2014;9(3):e93306.CrossRefPubMedPubMedCentral
30.
go back to reference de Juan Jimenez I, et al. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Fam Cancer. 2013;12(4):767–77.CrossRefPubMed de Juan Jimenez I, et al. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Fam Cancer. 2013;12(4):767–77.CrossRefPubMed
31.
go back to reference Peixoto A, et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat. 2009;114(1):31–8.CrossRefPubMed Peixoto A, et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat. 2009;114(1):31–8.CrossRefPubMed
32.
go back to reference Ewald IP, et al. BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome. Genet Mol Biol. 2016;39(2):223–31.CrossRefPubMedPubMedCentral Ewald IP, et al. BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome. Genet Mol Biol. 2016;39(2):223–31.CrossRefPubMedPubMedCentral
33.
go back to reference Weitzel JN, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1666–71.CrossRefPubMed Weitzel JN, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1666–71.CrossRefPubMed
34.
go back to reference de la Hoya M, et al. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clin Chem. 2006;52(8):1480–5.CrossRefPubMed de la Hoya M, et al. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clin Chem. 2006;52(8):1480–5.CrossRefPubMed
35.
go back to reference Torres D, et al. Absence of the BRCA1 del (exons 9–12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat. 2009;117(3):679–81.CrossRefPubMed Torres D, et al. Absence of the BRCA1 del (exons 9–12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat. 2009;117(3):679–81.CrossRefPubMed
36.
go back to reference Peixoto A, et al. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat. 2011;127(3):671–9.CrossRefPubMed Peixoto A, et al. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat. 2011;127(3):671–9.CrossRefPubMed
37.
go back to reference Ewald IP, et al. Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract. 2011;9:12.CrossRefPubMedPubMedCentral Ewald IP, et al. Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract. 2011;9:12.CrossRefPubMedPubMedCentral
38.
go back to reference Dufloth RM, et al. Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J. 2005;123(4):192–7.CrossRefPubMed Dufloth RM, et al. Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J. 2005;123(4):192–7.CrossRefPubMed
39.
go back to reference Gutierrez-Enriquez S, et al. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat. 2007;103(1):103–7.CrossRefPubMed Gutierrez-Enriquez S, et al. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat. 2007;103(1):103–7.CrossRefPubMed
40.
go back to reference Villarreal-Garza C, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer. 2015;121(3):372–8.CrossRefPubMed Villarreal-Garza C, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer. 2015;121(3):372–8.CrossRefPubMed
41.
go back to reference da Costa EC, et al. Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet. 2008;184(1):62–6.CrossRefPubMed da Costa EC, et al. Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet. 2008;184(1):62–6.CrossRefPubMed
42.
go back to reference Daly MB, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014;12(9):1326–38.PubMed Daly MB, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014;12(9):1326–38.PubMed
43.
go back to reference Levy DE, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13(4):349–55.CrossRefPubMedPubMedCentral Levy DE, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13(4):349–55.CrossRefPubMedPubMedCentral
45.
go back to reference Munck A, et al. Evaluation of guidelines for management of familial adenomatous polyposis in a multicenter pediatric cohort. J Pediatr Gastroenterol Nutr. 2011;53(3):296–302.CrossRefPubMed Munck A, et al. Evaluation of guidelines for management of familial adenomatous polyposis in a multicenter pediatric cohort. J Pediatr Gastroenterol Nutr. 2011;53(3):296–302.CrossRefPubMed
47.
go back to reference Kinzler KW, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991;253(5020):661–5.CrossRefPubMed Kinzler KW, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991;253(5020):661–5.CrossRefPubMed
48.
go back to reference Bisgaard ML, et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat. 1994;3(2):121–5.CrossRefPubMed Bisgaard ML, et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat. 1994;3(2):121–5.CrossRefPubMed
49.
go back to reference Torrezan GT, et al. Mutational spectrum of the APC and MUTYH genes and genotype-phenotype correlations in Brazilian FAP, AFAP, and MAP patients. Orphanet J Rare Dis. 2013;8:54.CrossRefPubMedPubMedCentral Torrezan GT, et al. Mutational spectrum of the APC and MUTYH genes and genotype-phenotype correlations in Brazilian FAP, AFAP, and MAP patients. Orphanet J Rare Dis. 2013;8:54.CrossRefPubMedPubMedCentral
50.
go back to reference Zeichner SB, et al. A De Novo Germline APC Mutation (3927del5) in a Patient with Familial Adenomatous Polyposis: Case Report and Literature Review. Clin Med Insights Oncol. 2012;6:315–23.CrossRefPubMedPubMedCentral Zeichner SB, et al. A De Novo Germline APC Mutation (3927del5) in a Patient with Familial Adenomatous Polyposis: Case Report and Literature Review. Clin Med Insights Oncol. 2012;6:315–23.CrossRefPubMedPubMedCentral
51.
go back to reference Ricker C, et al. Familial Adenomatous Polyposis (FAP) in 9 Hispanic women. Hered Cancer Clin Pract. 2010;2010(8):P18.CrossRef Ricker C, et al. Familial Adenomatous Polyposis (FAP) in 9 Hispanic women. Hered Cancer Clin Pract. 2010;2010(8):P18.CrossRef
52.
go back to reference Cruz-Correa M, et al. Clinical characterization and mutation spectrum in Hispanic families with adenomatous polyposis syndromes. Fam Cancer. 2013;12(3):555–62.CrossRefPubMedPubMedCentral Cruz-Correa M, et al. Clinical characterization and mutation spectrum in Hispanic families with adenomatous polyposis syndromes. Fam Cancer. 2013;12(3):555–62.CrossRefPubMedPubMedCentral
53.
go back to reference Plazzer JP, et al. The InSiGHT database: utilizing 100 years of insights into Lynch Syndrome. Fam Cancer. 2013;12:173–80.CrossRef Plazzer JP, et al. The InSiGHT database: utilizing 100 years of insights into Lynch Syndrome. Fam Cancer. 2013;12:173–80.CrossRef
54.
55.
go back to reference National Comprehensive Cancer Network. Genetic/familial high risk assessment: colorectal cancer. 2016. Version 1.2016. National Comprehensive Cancer Network. Genetic/familial high risk assessment: colorectal cancer. 2016. Version 1.2016.
56.
go back to reference Syngal S, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62. quiz 263.CrossRefPubMedPubMedCentral Syngal S, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62. quiz 263.CrossRefPubMedPubMedCentral
57.
go back to reference Aarnio M, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64(6):430–3.CrossRefPubMed Aarnio M, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64(6):430–3.CrossRefPubMed
59.
60.
go back to reference Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011;60(1):116–29.CrossRefPubMed Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011;60(1):116–29.CrossRefPubMed
61.
go back to reference Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21(6):1174–9.CrossRefPubMed Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21(6):1174–9.CrossRefPubMed
63.
go back to reference Vaccaro CA, et al. Hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in Argentina: report from a referral hospital register. Dis Colon Rectum. 2007;50(10):1604–11.CrossRefPubMed Vaccaro CA, et al. Hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in Argentina: report from a referral hospital register. Dis Colon Rectum. 2007;50(10):1604–11.CrossRefPubMed
64.
go back to reference Sarroca C, et al. Frequency of hereditary non-polyposis colorectal cancer among Uruguayan patients with colorectal cancer. Clin Genet. 2005;68(1):80–7.CrossRefPubMed Sarroca C, et al. Frequency of hereditary non-polyposis colorectal cancer among Uruguayan patients with colorectal cancer. Clin Genet. 2005;68(1):80–7.CrossRefPubMed
65.
go back to reference Giraldo A, et al. MLH1 and MSH2 mutations in Colombian families with hereditary nonpolyposis colorectal cancer (Lynch syndrome)--description of four novel mutations. Fam Cancer. 2005;4(4):285–90.CrossRefPubMed Giraldo A, et al. MLH1 and MSH2 mutations in Colombian families with hereditary nonpolyposis colorectal cancer (Lynch syndrome)--description of four novel mutations. Fam Cancer. 2005;4(4):285–90.CrossRefPubMed
66.
go back to reference Cruz-Correa M, et al. Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome. Fam Cancer. 2015;14(3):415–25.CrossRefPubMedPubMedCentral Cruz-Correa M, et al. Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome. Fam Cancer. 2015;14(3):415–25.CrossRefPubMedPubMedCentral
67.
go back to reference Weilandt AM, et al. Lynch Syndrome: selection of families by microsatellite instability and immunohistochemistry. Rev Medica Chile. 2012;140:1132–9.CrossRef Weilandt AM, et al. Lynch Syndrome: selection of families by microsatellite instability and immunohistochemistry. Rev Medica Chile. 2012;140:1132–9.CrossRef
68.
go back to reference Choi YH, et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract. 2009;7(1):14.CrossRefPubMedPubMedCentral Choi YH, et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract. 2009;7(1):14.CrossRefPubMedPubMedCentral
69.
go back to reference Barnetson RA, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354(26):2751–63.CrossRefPubMed Barnetson RA, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354(26):2751–63.CrossRefPubMed
70.
go back to reference Umar A, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.CrossRefPubMedPubMedCentral Umar A, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.CrossRefPubMedPubMedCentral
71.
go back to reference Giardiello FM, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014;109(8):1159–79.CrossRefPubMed Giardiello FM, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014;109(8):1159–79.CrossRefPubMed
72.
go back to reference Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10(4):293–300.CrossRefPubMedPubMedCentral Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10(4):293–300.CrossRefPubMedPubMedCentral
74.
go back to reference Robson M. Multigene panel testing: planning the next generation of research studies in clinical cancer genetics. J Clin Oncol. 2014;32(19):1987–9.CrossRefPubMed Robson M. Multigene panel testing: planning the next generation of research studies in clinical cancer genetics. J Clin Oncol. 2014;32(19):1987–9.CrossRefPubMed
75.
go back to reference Ortiz AP, et al. Awareness of direct-to-consumer genetic tests and use of genetic tests among Puerto Rican adults, 2009. Prev Chronic Dis. 2011;8(5):A110.PubMedPubMedCentral Ortiz AP, et al. Awareness of direct-to-consumer genetic tests and use of genetic tests among Puerto Rican adults, 2009. Prev Chronic Dis. 2011;8(5):A110.PubMedPubMedCentral
76.
go back to reference Delgado L, et al. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Res Treat. 2011;128(1):211–8.CrossRefPubMed Delgado L, et al. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Res Treat. 2011;128(1):211–8.CrossRefPubMed
77.
go back to reference Torres-Mejia G, et al. Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(3):498–505.CrossRefPubMed Torres-Mejia G, et al. Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(3):498–505.CrossRefPubMed
Metadata
Title
Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines
Authors
Marcia Cruz-Correa
Julyann Pérez-Mayoral
Julie Dutil
Miguel Echenique
Rafael Mosquera
Keila Rivera-Román
Sharee Umpierre
Segundo Rodriguez-Quilichini
Maria Gonzalez-Pons
Myrta I. Olivera
Sherly Pardo
on behalf of the Puerto Rico Clinical Cancer Genetics Consortia
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2017
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-017-0063-z

Other articles of this Issue 1/2017

Hereditary Cancer in Clinical Practice 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine